Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Learn when to select cash back over rewards cards for optimal benefits. Make informed credit choices now!
26,510 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
JPMorgan Chase CEO Jamie Dimon warns that markets may be riding an exuberant wave around AI and Big Tech, signaling ...
A celebrity’s return to the red carpet after a family loss highlights more than headlines—it spotlights money managem...
Oil jumped sharply in March 2026, but USOI investors faced capped upside and ongoing credit risk. The piece explains ...
A new era of autonomous AI agents could turbocharge voice tech leaders. Learn how agentic will supercharge soundhound...
Tech stocks just their footing as an AI spending surge loses steam. The sector faced a rough week, driven by slower d...
With rate-cut bets disappearing, traders pivot to potential rate hikes and Bitcoin’s role as a long-term hedge agains...
Grail's stock has slid as its Galleri MCED test faced a major trial setback. This piece breaks down what happened, wh...
A brief but frightening liquidity scare exposed vulnerabilities in the financial system. Regulators acted fast to con...
Markets stabilize after brief volatility, but a capital coward mindset keeps risk premia elevated and prices higher a...
A 32-year-old disabled caller seeks the moment to quit his job. Dave Ramsey outlines a practical 'bridge' plan, cente...
Small-cap stocks have staged a surprising comeback as the market navigates a higher-for-longer rate environment. Inve...